<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101972</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000415581</org_study_id>
    <secondary_id>RAVENBIO-RV-2004-002</secondary_id>
    <nct_id>NCT00101972</nct_id>
  </id_info>
  <brief_title>RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma</brief_title>
  <official_title>A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways.&#xD;
      Some block the ability of tumor cells to grow and spread. Others find tumor cells and help&#xD;
      kill them or carry tumor-killing substances to them.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating&#xD;
      patients with metastatic or recurrent adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of RAV12 in patients with metastatic or recurrent&#xD;
           adenocarcinoma.&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and immunogenicity of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive RAV12 IV over 2 hours 2-3 times per week in weeks 1-4 (course 1). Patients&#xD;
      are evaluated for response on day 43. Patients achieving a partial or complete response may&#xD;
      be eligible to receive additional courses of RAV12 as above. Courses repeat every 28 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of RAV12 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity. Up to 15 additional patients are treated at the MTD in 1&#xD;
      or more patients groups (e.g., colorectal, pancreatic, gastroesophageal, and other&#xD;
      adenocarcinoma).&#xD;
&#xD;
      After completion of study treatment, patients are followed within 4 weeks and then every 6-12&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity by CTCAE</measure>
    <time_frame>Days 1-50</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Days 1-50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RAV12 by serum levels</measure>
    <time_frame>Days 1, 2, 4, 5, 8, 15, 22, 29, 36, 43, and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity by Human Anti-chimeric antibodies</measure>
    <time_frame>Days 1, 8, 15, 22, and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression by clinical assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival by clinical assessment</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>RAV12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody RAV12</intervention_name>
    <description>Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks</description>
    <arm_group_label>RAV12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma&#xD;
&#xD;
               -  Metastatic or recurrent disease&#xD;
&#xD;
               -  Not curable by standard therapies&#xD;
&#xD;
          -  Must have failed at least 1, but no more than 3, prior therapies for metastatic or&#xD;
             recurrent disease&#xD;
&#xD;
               -  Patients with colorectal or breast adenocarcinoma must have failed at least 2&#xD;
                  prior therapies&#xD;
&#xD;
               -  Must have had at least stable disease for 3 months while on last treatment prior&#xD;
                  to most recent disease progression&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  At least 1 measurable site of disease ≥ 2 cm by radiography&#xD;
&#xD;
               -  Evaluable disease that could be reliably and consistently followed, as deemed by&#xD;
                  the principal investigator&#xD;
&#xD;
          -  RAAG12 expression confirmed* by immunohistochemistry NOTE: *Not required for patients&#xD;
             with colon, pancreatic, or gastric adenocarcinoma&#xD;
&#xD;
          -  No evidence of residual or recurrent CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL (transfusions allowed)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  γ-glutamyl transferase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Adequate hepatic function sufficient to undergo study therapy&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Adequate renal function sufficient to undergo study therapy&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No thrombosis within the past 3 months, including any of the following:&#xD;
&#xD;
               -  Deep vein thrombosis&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Stroke&#xD;
&#xD;
          -  Adequate cardiac function sufficient to undergo study therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolism within the past 3 months&#xD;
&#xD;
          -  No significant pulmonary compromise, particularly dependence on supplemental oxygen on&#xD;
             an as-needed or continuous basis&#xD;
&#xD;
          -  Adequate pulmonary function sufficient to undergo study therapy&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active viral, bacterial or systemic fungal infection requiring parenteral therapy&#xD;
             within the past 4 weeks&#xD;
&#xD;
          -  No history of chronic or recurrent infection requiring continual antiviral,&#xD;
             antifungal, or antibacterial agents&#xD;
&#xD;
          -  No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any&#xD;
             excipient contained in study drug&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Amylase and lipase normal&#xD;
&#xD;
          -  No other primary malignancy within the past 3 years except for the following:&#xD;
&#xD;
               -  Treated non-melanoma skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix by biopsy&#xD;
&#xD;
               -  Squamous intraepithelial lesion of the cervix by PAP smear&#xD;
&#xD;
               -  Localized prostate cancer (Gleason score &lt; 6)&#xD;
&#xD;
               -  Resected melanoma in situ&#xD;
&#xD;
          -  No other serious medical condition that would preclude study participation&#xD;
&#xD;
          -  No dementia or altered mental status that would preclude giving informed consent&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 half-lives since prior monoclonal antibody therapy&#xD;
&#xD;
          -  No concurrent vaccinations&#xD;
&#xD;
          -  No concurrent prophylactic hematologic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids except for the following:&#xD;
&#xD;
               -  Inhaled, ophthalmic, or nasal steroids&#xD;
&#xD;
               -  Stable dose of oral prednisone (or equivalent) ≤ 10 mg/day&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  Prior oral antiviral, antifungal, or antibacterial therapy allowed provided therapy&#xD;
             was completed within the past week&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive medications&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent vitamins except those approved by the medical monitor&#xD;
&#xD;
               -  Concurrent daily multivitamin allowed&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed provided patient is on stable dose for ≥ 1 month&#xD;
             prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanford J Stewart, MD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center at Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Burris HA 3rd, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, Kunkel LA, Loo D, Baughman J, Stewart SJ, Lewis N. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res. 2010 Mar 1;16(5):1673-81. doi: 10.1158/1078-0432.CCR-09-2263. Epub 2010 Feb 23.</citation>
    <PMID>20179219</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>January 18, 2005</study_first_submitted>
  <study_first_submitted_qc>January 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2005</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the bladder</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>adenocarcinoma of the gallbladder</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma with squamous metaplasia of the gallbladder</keyword>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>vaginal adenocarcinoma</keyword>
  <keyword>vaginal clear cell adenocarcinoma</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage IVA vaginal cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IVB vaginal cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>recurrent vaginal cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

